BMI View: Austria's economy is set to grow at a faster clip in the second half of 2014 and domestic
consumer demand is poised to strengthen in this period. We have revised the healthcare and
pharmaceutical market forecast slightly upwards to reflect this. The EUR-USD ..."
BMI View: We believe Austria's pharmaceutical spending will post weak growth over the medium term, due
to the state's need to contain fiscal deficits. Although an improving economic climate in Austria's primary
trading partner, Germany, has improved outlook for the in ..."
BMI View: The Austrian pharmaceutical market is relatively small in absolute terms in comparison with its
EU15 neighbours, yet has one of the highest global per capita expenditures on healthcare. This is due to its
relatively small population, high burden of non-commu ..."
The macroenvironment for the Austrian pharmaceutical industry is positive. Economic recovery is strengthening, with modest GDP real growth projected in 2012 and 2013. However, the EIU projects that Austria will be affected by the expected euro zone recession. Legally, laws on int ..."